Hansoh Pharmaceutical (03692.HK) Rises Over 3% as HS-20110 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

According to the Zhitong Finance APP, Hansoh Pharma (03692) rose over 3%. As of the time of writing, it increased by 2.81%, trading at HK$18.28, with a turnover of HK$51.8539 million.

On the news front, Hansoh Pharma announced that on December 16, 2024, the group's self-developed novel antibody-drug conjugate (ADC) HS-20110 for injection received clinical trial approval from the National Medical Products Administration (NMPA) of China, and is planned to be used in clinical trials for advanced solid tumors.